Ultralow-Dose Radiation Relieves Myeloma Bone Pain and Keeps Marrow Intact
A phase II trial finds 4 Gy or less delivers 86% pain response at 6 months in myeloma patients, preserving marrow for future therapies.
Summary
A prospective phase II trial tested ultralow-dose radiation therapy — either a single 4-Gy dose or two 2-Gy doses — for bone pain caused by multiple myeloma. Standard palliative radiation typically delivers 30 Gy across 10 fractions. The new approach achieved a 67% pain response rate at 4 weeks, climbing to 86% at 6 months. Crucially, bone marrow was not damaged, allowing patients to continue chemotherapy, maintain blood counts, and remain eligible for transplant or CAR T-cell therapy. Adverse events were minor and infrequent. Only 19% of patients needed a second radiation course. Researchers presented these findings at the ASTRO annual meeting, suggesting the approach is ready for clinical practice with appropriate patient counseling.
Detailed Summary
Multiple myeloma frequently causes painful bone lesions that require radiation therapy, but standard treatment doses can deplete bone marrow, limiting future treatment options including stem cell transplants and CAR T-cell therapy. A new prospective clinical trial tested whether dramatically lower radiation doses could still relieve pain while preserving marrow function — a critical question as myeloma survival has improved significantly and patients now live long enough to need multiple lines of therapy.
The phase II trial enrolled 69 evaluable patients who received either a single 4-Gy dose or two fractions of 2 Gy each — doses roughly seven to fifteen times lower than the standard 30-Gy palliative regimen. At four weeks, two-thirds of patients had a complete or partial pain response. By six months, that figure rose to 86%, comparing favorably to historical controls treated with conventional doses.
Safety results were equally encouraging. Only five of 69 patients experienced treatment-related adverse events, none of which reached grade 3 severity or required any interruption of therapy. Bone marrow status remained intact across the cohort, allowing patients to continue systemic chemotherapy and keeping them eligible for re-irradiation, transplant, or emerging cellular therapies at any future point.
Presenting physician Leslie Ballas, MD, of Cedars-Sinai Medical Center noted that prior evidence in this area was largely retrospective. She argued the prospective data are now strong enough to support adoption in clinical practice, provided patients understand it is a risk-adapted strategy where a minority — about 19% — may eventually need a second radiation course.
For myeloma patients, who increasingly survive a decade or more, preserving bone marrow reserve is a genuine longevity and functional-capacity issue. This approach may allow earlier, more confident use of radiation to control pain without foreclosing future life-extending therapies.
Key Findings
- 86% of myeloma patients achieved pain relief at 6 months with doses as low as 4 Gy total
- Ultralow-dose RT caused no grade 3 or higher adverse events in any of 69 patients
- Bone marrow was fully preserved, keeping transplant and CAR T-cell therapy options open
- Only 19% of patients needed re-irradiation, and it remained available at any later point
- Investigators say evidence is sufficient for immediate clinical practice adoption
Methodology
This is a meeting-coverage news report from MedPage Today summarizing a prospective single-arm phase II clinical trial presented at the ASTRO 2026 annual meeting. The trial enrolled 69 evaluable patients and compared outcomes to historical controls rather than a concurrent randomized arm, which limits causal inference. The reporting source is a credible medical news outlet with specialist editorial oversight.
Study Limitations
Results come from a single-arm phase II trial without a concurrent randomized comparator, so outcomes are benchmarked against historical controls. The article is a conference presentation summary and the full dataset has not yet been peer-reviewed or published. Long-term durability of pain response beyond six months and impact on overall survival were not reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: